Pacira BioSciences, Inc. PCRX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 79.3%0.0pp | 79.4%+0.2pp | 79.2%+1.0pp | 78.2%+0.6pp | 77.6%+1.9pp | |
| Operating margin | 3.3%+0.6pp | 2.6%— | —— | —— | —— | |
| Net margin | 0.7%-0.3pp | 1%— | —— | —— | —— | |
| EBITDA margin | 15.7%+0.5pp | 15.2%— | —— | —— | —— | |
| Free cash flow margin | 18.1%-0.8pp | 18.8%+1.5pp | 17.3%+0.7pp | 16.6%-6.1pp | 22.7%-2.8pp | |
| Returns | ||||||
| Return on equity | 0.7%-0.2pp | 1%— | —— | —— | —— | |
| Return on assets | 0.4%-0.1pp | 0.5%— | —— | —— | —— | |
| Return on invested capital | 2.7%+0.8pp | 1.9%— | —— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.5×+0.1× | 0.4×0.0× | 0.4×0.0× | |
| Inventory turnover | 1.1×0.0× | 1.1×0.0× | 1.1×-0.1× | 1.2×-0.1× | 1.4×-0.1× | |
| Liquidity | ||||||
| Current ratio | 4.7×+0.2× | 4.5×-0.7× | 5.3×+2.9× | 2.4×0.0× | 2.4×0.0× | |
| Quick ratio | 3.4×+0.1× | 3.3×-0.5× | 3.8×+1.9× | 1.9×-0.1× | 2×0.0× | |
| Cash ratio | 1.3×0.0× | 1.3×-0.1× | 1.4×+0.4× | 1×+0.1× | 0.9×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.6×0.0× | 0.6×0.0× | 0.6×+0.1× | 0.5×0.0× | 0.4×-0.3× | |
| Debt-to-assets | 0.3×0.0× | 0.3×0.0× | 0.3×+0.1× | 0.2×0.0× | 0.2×-0.1× | |
| Net debt / EBITDA | 2.3×0.0× | 2.4×— | —— | —— | —— | |
| Interest coverage | 1.5×+0.4× | 1.1×— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $15.98+3.9% | $15.39-5.9% | $16.36-1.9% | $16.67-2.9% | $17.16+2.0% | |
| Valuation | ||||||
| Market capitalization | $942.78M-14.5% | $1.11B-3.8% | $1.16B+1.6% | $1.14B-0.9% | $1.15B+32.2% | |
| Enterprise value | $1.21B+2.6% | $1.37B-4.4% | $1.44B+20.6% | $1.19B-2.6% | $1.22B+5.9% | |
| Price / earnings | 183.5×— | 158.3×— | —— | —— | —— | |
| Price / sales | 1.3×-0.3× | 1.5×-0.1× | 1.6×0.0× | 1.6×0.0× | 1.6×+0.4× | |
| Price / book | 1.5×+0.1× | 1.6×0.0× | 1.6×+0.1× | 1.5×+0.1× | 1.4×+0.3× | |
| EV / EBITDA | 10.6×— | 12.5×— | —— | —— | —— | |
| EV / sales | 1.7×0.0× | 1.9×-0.1× | 2×+0.3× | 1.7×-0.1× | 1.7×+0.1× | |
| Free cash flow yield | 13.8%-0.4pp | 12.3%+1.5pp | 10.7%+0.5pp | 10.3%-3.6pp | 13.9%-6.7pp | |
| Earnings yield | 0.5%— | 0.6%— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Pacira BioSciences, Inc.'s profit margins?
- Pacira BioSciences, Inc. (PCRX) runs a 79.3% gross margin and a 3.3% operating margin, with a 0.7% net margin.
- Where do Pacira BioSciences, Inc.'s ratios come from?
- Every ratio is computed from Pacira BioSciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
